IncobotulinumtoxinA (Xeomin) for Upper Limb Spasticity (NT-Spin)
Prospective, Randomized, Observer-blind, Parallel-group, Multi-center Trial to Assess Efficacy and Safety of Two Different Dilutions of incobotulinumtoxinA (Xeomin) in Patients With Upper Limb Spasticity
Sponsor: Merz Pharmaceuticals GmbH
This PHASE3 trial investigates Upper Limb Spasticity and is currently completed. Merz Pharmaceuticals GmbH leads this study, which shows 7 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Feb 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Merz Pharmaceuticals GmbH
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Barcelona, Spain , Bari, Italy , Beelitz-Heilstätten, Germany , Bern, Switzerland , Besançon, France , Costa Masnaga, Italy , Düsseldorf, Germany , Garches, France , Gladbeck, Germany , Hermagor, Austria and 17 more locations